---
title: "0101: Analysis round three: no candidate yet; entry 010 relabeled other"
owner: "@SolarnodeCC"
status: approved
last_reviewed: 2026-11-13
related: [REQ-AGENT-001, REQ-AGENT-006, REQ-TEST-005]
---

# 0101: Analysis round three: no candidate yet; entry 010 relabeled other

- Decision status: Accepted
- Date: 2026-11-13
- Changes: the required industries and the `handoff` industry of `gs-research-analyst-010`; the row of OQ-036 in [open questions](../open-questions.md). No requirement or prompt changes.

## Context

Research Analyst and Relevance ran on 13 November 2026 with `research-analyst@2` and `relevance@3`, which state the owner's industry rules ([ADR 0100](0100-analysis-rerun-and-industry-rules-in-the-prompts.md), [results](../test/analysis-benchmark-round-three-results.md)):

| Agent | Gemma, thinking off | DeepSeek | Run passes at |
|---|---|---|---|
| Research Analyst | 57.6 / 57.6 / 57.6 % | 69.7 / 66.7 / 75.8 % | 0.70 |
| Relevance | 57.6 / 54.5 / 51.5 % | 60.6 / 63.6 / 60.6 % | 0.80 |

The rules worked where they apply: DeepSeek's industry failures fell from 7 to 3 and Gemma's strategic-relevance failures from 39 to 22. All three of DeepSeek's remaining industry failures are on `gs-research-analyst-010`, which still required `life-sciences` for radiologists, the tension that ADR 0100 left for the owner.

## Decision

The owner chose, on 2026-11-13:

- **`gs-research-analyst-010` requires `other`.** Radiologists are care providers, and `research-analyst@2` makes care providers `other`; the note of ADR 0099 that counted radiology reporting as diagnostics gives way. The `handoff` industry follows. The Relevance entry stays as it is: best industry `life-sciences`, indirect band.
- **No candidate is chosen for Research Analyst or Relevance.** Rescored against the relabel, DeepSeek passes Research Analyst at 72.7 / 69.7 / 78.8 %, and the second run still misses the 0.70 floor by one entry.
- **The remaining failures stay as the owner decided them.** Most of DeepSeek's Research Analyst failures are Novelty ranges on 009, 017, 018, 023, and 025, which ADR 0099 kept. Effort is the largest Relevance failure for both candidates, and ADR 0099 kept the effort labels. Neither is changed here.

## Consequences

- OQ-036 stays open for Research Analyst and Relevance. A next step would review the Novelty ranges or the effort scale; either needs its own ADR and a new run.
- `gs-problem-discovery-010` still names `life-sciences` as the customer industry, while the golden-set README keeps care providers as `other` for Problem Discovery too. It is reviewed with the Problem Discovery facts (ADR 0095).
- Round three cost EUR 0.44 (399 calls, USD 0.4946), the same as the gateway logs record.
